An Open-label, Randomized, Single-dose, Three-way Crossover Study to Establish Bioequivalence of 5 mg Mavacamten Capsule 1 and 5 × 1 mg Mavacamten Capsule 2 to 5 mg Mavacamten Capsule 2 in Healthy Participants
Latest Information Update: 13 Oct 2023
At a glance
- Drugs Mavacamten (Primary)
- Indications Heart failure; Hypertrophic cardiomyopathy
- Focus Pharmacokinetics
- Sponsors Bristol-Myers Squibb
- 10 Oct 2023 Status changed from recruiting to completed.
- 23 May 2023 Status changed from not yet recruiting to recruiting.
- 21 Dec 2022 New trial record